Supernus Pharma (SUPN) Misses Q1 EPS by 13c, Revenues Beat; Offers FY21 Revenues Outlook

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.11, $0.13 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $130.9 million versus the consensus estimate of $129.2 million.

“The approval of Qelbree provides pediatric patients living with ADHD a therapy with proven efficacy and a tolerable safety profile, and that is not a controlled substance,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “Our Qelbree commercial launch activities are ongoing and include engagement with both physicians and patient groups who have expressed great interest in this unique new alternative for the treatment of ADHD.”

GUIDANCE:

Supernus Pharma sees FY2021 revenue of $550-580 million, versus the consensus of $569.54 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• U.S. Bank hires Eric Levine to head healthcare payments unit
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth